2023 Fall Clinical Virtual Grand Rounds

2023 Virtual Grand Rounds Session 10: September 6, 2023 - Case Conversations: Optimizing PDT In Your Practice One Patient at a Time

About

Fall Clinical Virtual Grand Rounds consist of regularly scheduled CME sessions on a variety of dermatological diseases and tools, delivered by the top experts in dermatology. Please join us for this week's session:

Wednesday, September 6, 2023

8 PM ET / 5 PM PT

Case Conversations: Optimizing PDT in Your Practice One Patient at a Time

 

This activity is supported by an educational grant from Biofrontera.

Availability

In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:

Release Date:

September 7, 2023

Expiration Date:

September 7, 2024

Learning Objectives

At the completion of this activity, participants should be better able to:

  • Describe the key data on photodynamic therapy to manage actinic keratosis

  • Identify patients with actinic keratosis for photodynamic therapy

  • Discuss strategies to optimize care of patients with actinic keratosis with photodynamic therapy

Intended Audience
This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.
Faculty
Ashish
Ashish Bhatia

Associate Professor of Clinical Dermatology
Northwestern University
Feinberg School of Medicine
Chicago, IL

Anthony
Anthony Rossi, MD

Assistant Attending
Memorial Sloan Kettering Cancer Center
New York, NY

Linda
Linda Stein Gold, MD

Director Clinical Research 
Henry Ford Health System 
Detroit, MI

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Institute for Continuing Healthcare Education and CMEsquared. The Institute is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The Institute for Continuing Healthcare Education designates this live and enduring activity for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures & Disclaimers

CONFLICTS OF INTEREST/DISCLOSURES

In accordance with the ACCME Standards for Commercial Support, balance, independence, objectivity, and scientific rigor are ensured in all CME activities. This requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with any ineligible companies. In addition, the content of this material has been approved by an independent peer reviewer. 

Disclosures are as follows:

Ashish C. Bhatia

Advisory Board/Consultant: Alastin Skincare, Allergan/AbbVie, Avita Medical, Bausch Health, Carpe, Cutera, Cytrellis, Emblation, Ltd., Entrepix Medical, Evolus Medline, MiMedx, Ortho Dermatologics, Revance, Solta, SofWave, Strata Skin Sciences, Theravant Corp

Board Member: Theravant Corporation, DermEd Foundation

Shareholder: Biomarck, Carpe, Cuera, DermMD, Ganzum, SimSkin, Sonoma, Theravant Corporation, Zalea

Grant/Research Supporter: Abbvie, Alastin Skincare, Avita Medical, Cutera, Medline, Novascan, Pulse Bioscienceds, R2 Technologies, Revance

Speaker's Bureau: Allergan, Cutera, DermEd Foundation, Evolus, Medline, MiMedx, Ortho Dermatologics, Paradigm, Revance, Theravant Corp.

Intellectual Property/Patents: BioMarck

Anthony Rossi, MD

Advisory Board: Allergan 

Consultant: Almirall, Biofrontera, Evolus Mavig, Merz, Dynamed, Canfield Scientific, Allergan, Lam Therapeutics, Regeneron, Cutera, Skinfix

Employee/owner: DAR companies (Founder)

Grant/Research Support: Biofrontera, Regeneron, LEO, 

Linda F. Stein Gold, MD

Grant/Research Support: Arcutis, BMS, Incyte, Dermavant, Galderma, Lilly, AbbVie

Consultant: Arcutis, BMS, Incyte, Dermavant, Galderma, Lilly, AbbVie

Speakers’ Bureau or Honoraria: Leo, AbbVie, Almirall, Galderma, Pfizer, Sanofi, Regeneron

The planners have disclosed that they have no relevant financial relationships with any Ineligible Company in the past 24 months.  

The Institute discloses that all relevant conflicts have been satisfactorily mitigated.